Esperion Therapeutics, Inc.
ESPR
$2.51
-$0.21-7.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 143.73% | 69.10% | 11.58% | -52.81% | 114.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 143.73% | 69.10% | 11.58% | -52.81% | 114.30% |
| Cost of Revenue | 14.13% | 100.20% | 32.18% | 87.81% | 25.40% |
| Gross Profit | 289.68% | 33.15% | -0.34% | -81.71% | 963.65% |
| SG&A Expenses | 12.21% | 4.69% | -10.58% | 2.40% | -18.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.16% | 43.76% | 5.66% | 33.03% | -1.45% |
| Operating Income | 2,028.35% | 37.86% | 175.11% | -130.57% | 89.57% |
| Income Before Tax | 398.68% | -6.13% | 79.45% | -166.30% | 62.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 390.04% | -6.13% | 79.45% | -166.30% | 62.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 390.04% | -6.13% | 79.45% | -166.30% | 62.16% |
| EBIT | 2,028.35% | 37.86% | 175.11% | -130.57% | 89.57% |
| EBITDA | 2,040.79% | 37.92% | 175.62% | -130.52% | 89.63% |
| EPS Basic | 339.63% | -3.04% | 80.37% | -157.23% | 78.26% |
| Normalized Basic EPS | 367.68% | -3.06% | -39.93% | -157.21% | 79.96% |
| EPS Diluted | 299.36% | -3.04% | 80.37% | -162.56% | 78.26% |
| Normalized Diluted EPS | 322.61% | -3.06% | -39.93% | -164.10% | 79.96% |
| Average Basic Shares Outstanding | 21.02% | 2.98% | 4.64% | 15.87% | 73.99% |
| Average Diluted Shares Outstanding | 45.51% | 2.98% | 4.64% | 3.42% | 73.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |